Over the past five years, Eli Lilly stock has risen roughly 320% as of market close Aug. 11. Meanwhile, the company has ...

The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...

LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

How do we make Chili’s relevant again?” he asked. “How do we remind people why they loved this brand in the first place?” In ...

Danone is introducing an Oikos brand drink targeting U.S. consumers using weight loss medications such as Wegovy, pledging ...

Chinese drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...

Recent medical news supports the reasoning behind the innovative Wellness Incentive Program offered by Teachers Health Trust ...

Shares of Eli Lilly (NYSE: LLY), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...